Search Grant Opportunities

Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required)

ID: RFA-CA-25-009 • Type: Posted

Description

Posted: Oct. 1, 2024, 12:00 a.m. EDT
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to advance the science of scale-up and sustainment of lung cancer screening (LCS) for populations at high risk for lung cancer. This NOFO will support studies that will identify the most effective implementation strategies for scaling-up and sustaining the delivery of LCS across a range of clinical care settings and diverse populations at high risk for lung cancer. This NOFO will use the UG3/UH3 phased cooperative agreement mechanism. The UG3 phase will support preparatory activities for the scale-up and sustainment trial. The UH3 phase will support the scale-up and sustainment trial.
Posted: July 19, 2024, 12:00 a.m. EDT
Posted: July 19, 2024, 12:00 a.m. EDT
Background
The National Cancer Institute (NCI), part of the Department of Health and Human Services, aims to advance the science of scaling up and sustaining lung cancer screening (LCS) for populations at high risk for lung cancer.

This funding opportunity seeks to support research projects that will identify effective implementation strategies for delivering LCS across diverse clinical settings, particularly focusing on populations experiencing health inequities.

Grant Details
This Notice of Funding Opportunity (NOFO) invites proposals for Research Projects aimed at advancing the science of scale-up and sustainment of lung cancer screening (LCS). Each project must propose a randomized controlled trial design to test implementation strategies that equitably and effectively scale-up LCS delivery.

Key tasks include: conducting trials at a minimum of 60 diverse sites, focusing on all essential processes of LCS, measuring service delivery at least 12 months post-implementation, and utilizing validated measures aligned with the SUMMIT Initiative.

The UG3 phase will support preparatory activities while the UH3 phase will focus on conducting the trial.

Eligibility Requirements
Eligible applicants include higher education institutions, nonprofits, for-profit organizations, local governments, state governments, tribal governments, and other entities. Institutions are encouraged to include diverse perspectives in their teams. Only one application per institution is allowed.

Period of Performance
The grant has a maximum project period of two years for the UG3 phase and four years for the UH3 phase.

Grant Value
NCI intends to commit $2,400,000 to fund up to 3 awards in FY 2025. Application budgets may not exceed $500,000 in direct costs per year for the UG3 phase and $850,000 in direct costs per year for the UH3 phase.

Place of Performance
The grant activities will be performed across various clinical care settings in the United States.

Overview

Category of Funding
Education
Health
Funding Instruments
Cooperative Agreement
Grant Program (CFDA)
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 10/1/24 the National Institutes of Health posted grant opportunity RFA-CA-25-009 for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT)- Lung Cancer Screening (UG3/UH3 Clinical Trial Required). The grant will be issued under grant program 93.399 Cancer Control.

Timing

Posted Date
Oct. 1, 2024, 12:00 a.m. EDT
Closing Date
Dec. 6, 2024, 12:00 a.m. EST Due in 1 Days
Last Updated
Oct. 2, 2024, 12:09 p.m. EDT
Version
1
Archive Date
Jan. 11, 2025

Eligibility

Eligible Applicants
County governments
Private institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
City or township governments
For profit organizations other than small businesses
Independent school districts
Public and State controlled institutions of higher education
Others (see text field entitled "Additional Information on Eligibility" for clarification)
State governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Small businesses
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Special district governments
Additional Info
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Contact Phone
(301) 402-2541
Additional Information
https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-25-009.html

Documents

Posted documents for RFA-CA-25-009

Potential Applicants and Partners

Awardees that have recently won grants similar to RFA-CA-25-009

Incumbent or Similar Grants

Grants similar to RFA-CA-25-009

Similar Active Opportunities

Open grant opportunities similar to RFA-CA-25-009